このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Intellia Therapeutics 過去の業績
過去 基準チェック /06
Intellia Therapeuticsの収益は年間平均-37.1%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間15.5% 3.3%割合で 増加しています。
主要情報
-35.2%
収益成長率
-23.7%
EPS成長率
Biotechs 業界の成長 | 17.0% |
収益成長率 | 1.8% |
株主資本利益率 | -52.4% |
ネット・マージン | -1,106.9% |
前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case
Sep 25We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate
Sep 07Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)
Aug 03Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year
Jun 06Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Jun 05Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
May 14Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
May 13Intellia Therapeutics Is On The Move
Feb 29Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier
Feb 09Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?
Jan 01Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20Intellia Therapeutics: Top Speculative Trade In The Biotech Space
Oct 05Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling
Sep 01Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?
Aug 06Intellia Therapeutics down 12% following bottom line Q2 earnings miss
Aug 04Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish
Jul 28Intellia Therapeutics: Several Catalysts Expected For H2 2022
May 12Intellia: One Patent Ruling Turns The Industry Upside Down
Mar 09Intellia Therapeutics: A Lot Of News Can Bring The Stock Up
Feb 25Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022
Feb 09Intellia: Best All-Around Gene Editing Company
Jan 27We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth
Dec 31Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans
Dec 15Intellia Stock: Setting Up For Success
Nov 29Intellia: A Step Closer To A Life-Changing Cure
Nov 21Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price
Oct 11Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon
Aug 31収支内訳
収支内訳
Intellia Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Jun 24 | 46 | -509 | 121 | 0 |
31 Mar 24 | 53 | -486 | 120 | 0 |
31 Dec 23 | 36 | -481 | 116 | 0 |
30 Sep 23 | 52 | -462 | 111 | 0 |
30 Jun 23 | 53 | -453 | 104 | 0 |
31 Mar 23 | 53 | -430 | 95 | 0 |
31 Dec 22 | 52 | -474 | 90 | 0 |
30 Sep 22 | 51 | -442 | 89 | 0 |
30 Jun 22 | 45 | -400 | 85 | 0 |
31 Mar 22 | 38 | -369 | 80 | 0 |
31 Dec 21 | 33 | -268 | 71 | 0 |
30 Sep 21 | 27 | -229 | 60 | 0 |
30 Jun 21 | 42 | -185 | 52 | 0 |
31 Mar 21 | 52 | -149 | 46 | 0 |
31 Dec 20 | 58 | -134 | 44 | 0 |
30 Sep 20 | 62 | -120 | 42 | 0 |
30 Jun 20 | 51 | -116 | 40 | 0 |
31 Mar 20 | 46 | -109 | 42 | 0 |
31 Dec 19 | 43 | -100 | 41 | 0 |
30 Sep 19 | 40 | -90 | 41 | 0 |
30 Jun 19 | 37 | -89 | 41 | 0 |
31 Mar 19 | 33 | -86 | 35 | 0 |
31 Dec 18 | 30 | -85 | 32 | 0 |
30 Sep 18 | 29 | -90 | 34 | 0 |
30 Jun 18 | 29 | -83 | 31 | 0 |
31 Mar 18 | 27 | -76 | 30 | 0 |
31 Dec 17 | 26 | -68 | 28 | 0 |
30 Sep 17 | 25 | -54 | 23 | 0 |
30 Jun 17 | 23 | -46 | 22 | 0 |
31 Mar 17 | 21 | -38 | 19 | 0 |
31 Dec 16 | 16 | -32 | 17 | 0 |
30 Sep 16 | 13 | -26 | 14 | 0 |
30 Jun 16 | 9 | -22 | 11 | 0 |
31 Mar 16 | 7 | -18 | 10 | 0 |
31 Dec 15 | 6 | -12 | 8 | 0 |
30 Sep 15 | 4 | -14 | 8 | 0 |
質の高い収益: NTLAは現在利益が出ていません。
利益率の向上: NTLAは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: NTLAは利益が出ておらず、過去 5 年間で損失は年間37.1%の割合で増加しています。
成長の加速: NTLAの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: NTLAは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。
株主資本利益率
高いROE: NTLAは現在利益が出ていないため、自己資本利益率 ( -46.86% ) はマイナスです。